The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

In Vitro ADME Testing Services Market, 2019-2030

  • Lowest Price Guaranteed From USD 3,999

  • Published
    January 2019

  • Pages
    317

  • View Count
    3400

Example Insights

 

 

Overview

Earlier, customers from North America demonstrated a preference for service providers within the US to outsource their ADME requirements; however, clients are now more willing to work across borders. Despite growing activity in other upcoming regions, I believe that the major proportion of activity in this field is still restricted to within North America, followed by Asia-Pacific and Europe.

-- Chief Scientific Officer, a US-based small-sized CRO

The early stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the overall success of a drug candidate in both preclinical and clinical studies. It is also important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent in R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early stage therapeutic candidates are able to make it past preclinical evaluation. According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity. As a result, the industry is currently under tremendous pressure to not only meet the expectations of a growing patient population, but to also identify ways to mitigate the risks associated with discovery programs of novel drug / therapy molecules.

Specifically, ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical / biopharmaceutical market. Moreover, advances in combinatorial chemistry and high throughput screening in the last decade have made it possible to carry out early stage ADME screening for a large number of compounds in a more cost and time efficient manner. In less than a decade, the ADME services industry has witnessed noteworthy consolidation, with many of the smaller players being acquired by more established firms in efforts to augment services portfolios and widen geographical reach. Further, given the growing demand for high quality pharmacological interventions, and the cost and time-related benefits of outsourcing in vitro ADME research, the demand for CROs is projected to grow significantly in the foreseen future.

 

Scope of the Report

The "In Vitro ADME Testing Service Market, 2019-2030" report features a comprehensive study of the current landscape of in vitro ADME testing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring a comprehensive list of over 90 CROs that offer in vitro ADME testing services, and analyses based on a number of parameters, such as year of establishment, headquarter location(s), company size, type of additional service(s) offered (in vivo ADME, in silico ADME and toxicology testing), range of assays offered within in vitro ADME service portfolio (blood to plasma ratio, Caco-2 permeability, cytochrome (CYP) enzyme induction / inhibition, metabolic stability, plasma protein binding, reaction phenotyping and others), type of molecule(s) (biologics and small molecules), and type of clientele (pharmaceutical / biotechnology companies and academic / research institutes).
  • A schematic logo landscape of in vitro ADME service providers, highlighting their geographical distribution (on the basis of location of headquarters) and company size (small-sized (1-50 employees), mid-sized (51-200 employees), large (201-1,000 employees), and very large (>1,000 employees)).
  • A discussion on the various outsourcing business models adopted in this domain, along with a list of key considerations that need to be taken into account by industry stakeholders while selecting a CRO partner.
  • Elaborate profiles of popular in vitro ADME testing service providers, featuring a brief overview of the company, its financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018, along with the geographical distribution of this activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
  • A detailed discussion on the various regulatory guidelines related to in vitro ADME testing, which have been laid down by major international / regional regulatory bodies (namely European Medicine Agency (EMA), US Food and Drug Administration (USFDA), Ministry of Health, Labor and Welfare (MHLW), International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use, the Organisation for Economic Co-operation and Development (OECD), and World Health Organization (WHO)).

One of the key objectives of the report is to evaluate the current opportunity and the future potential of the in vitro ADME testing services market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D]  type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories). To account for the uncertainties associated with the in vitro ADME testing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions conducted with several stakeholders in this industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.​​​

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the in vitro ADME testing services market and its likely evolution in the short-mid and long term.

Chapter 3 provides an introduction to the overall drug discovery process, with details on the time taken for a drug to traverse through the various stages of drug development and into the market. It includes an overview of ADME testing, featuring a detailed discussion on the significance of evaluating various ADME parameters within the drug discovery and development process. Further, the chapter presents insights on the benefits of carrying out ADME testing at early stages of drug development. It also features details related to various contract services that can be availed by industry stakeholders seeking to outsource ADME testing.

Chapter 4 features a detailed discussion on the various outsourcing related business models that are commonly adopted by the industry stakeholders in relation to ADME testing. The chapter includes a list of factors that drive sponsors to outsource their ADME testing operations. It also highlights several key parameters that sponsors need to take into consideration while choosing a CRO partner. The chapter features an elaborate discussion on benefits of outsourcing ADME services, along with the affiliated risks and challenges.

Chapter 5 provides a comprehensive view on the global landscape of in vitro ADME testing service providers. It includes information related to over 90 CROs that claim to offer in vitro ADME services, featuring in-depth analyses of the players based on their year of establishment, headquarter location(s), company size, type of additional service(s) offered, range of assays offered within in vitro ADME service portfolio, type of molecule(s), and type of clientele. The chapter also includes a list of 70 players offering in silico ADME services. In addition, it also features a logo landscape of the players that claim to offer in vitro ADME services, distributed on the basis of the location of their respective headquarters and company size.

Chapter 6 features detailed profiles of key CROs that claim to offer in vitro ADME testing services, across different geographies. Each company profile includes a brief overview of the company, financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to in vitro ADME testing. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 8 features a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2005 to 2018. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.

Chapter 9 features information on the regulatory guidelines that have been laid down by key regulatory bodies / organizations, specific to ADME testing in the pharmaceutical industry. These are EMA, ICH, MHLW, OECD, USFDA and WHO.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of in vitro ADME testing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the biopharmaceutical industry.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Dan Close (Chief Scientific Officer, 490 BioTech), and Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. Chapter Overview
3.2. The Drug Discovery and Development Process
3.3. Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing
3.3.1. Absorption
3.3.2. Distribution
3.3.3. Metabolism
3.3.4. Excretion
3.4. Importance of ADME Studies in Early Stage Research
3.5. Types of ADME Studies in Discovery and Preclinical Development
3.6. Types of Assays Used in ADME Testing
3.7. Types of ADME Testing Studies
3.7.1. In Vitro ADME Testing Studies
3.7.2. In Silico ADME Testing Studies
3.7.3. In Vivo ADME Testing Studies
3.8. Key Drivers for ADME Testing Studies
3.9. Concluding Remarks

4 GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing ADME Testing Services
4.3. Guiding Models for Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance-based Outsourcing Model
4.3.3. Outcomes-based Outsourcing Model
4.3.4. Phase-dependent Outsourcing Model
4.4. Selecting a Contract Research Organization (CRO) Partner
4.4.1. Key Considerations
4.5. Role of CROs in Drug Development
4.5.1. Discovery and Preclinical Research
4.5.2. Early Clinical Research
4.5.3. Late Stage Clinical Research
4.6. Benefits of Outsourcing ADME Testing Services
4.7. Risks and Challenges Associated with Outsourcing ADME Testing Services
4.8. Concluding Remarks

5 MARKET LANDSCAPE
5.1. Chapter Overview
5.2. In Vitro ADME Testing Services: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Service Offering
5.2.5. Analysis by Type of In Vitro ADME Assays
5.2.6. Analysis by Type of Molecule
5.2.7. Analysis by Type of Clientele
5.2.8. Logo Landscape: Distribution by Company Size and Location of Headquarters
5.3. In Silico ADME Testing Services: List of Industry Players

6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Albany Molecular Research (AMRI)
6.2.1.1. Company Snapshot
6.2.1.2. Financial Information
6.2.1.3. ADME Testing Specific Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Charles River Laboratories
6.2.2.1. Company Snapshot
6.2.2.2. Financial Information
6.2.2.3. ADME Testing Specific Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Pharmaceutical Product Development (PPD)
6.2.3.1. Company Snapshot
6.2.3.2. ADME Testing Specific Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. RTI International
6.2.4.1. Company Snapshot
6.2.4.2. Financial Information
6.2.4.3. ADME Testing Specific Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. Eurofins Scientific
6.3.1.1. Company Snapshot
6.3.1.2. Financial Information
6.3.1.3. ADME Testing Specific Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Evotec
6.3.2.1. Company Snapshot
6.3.2.2. Financial Information
6.3.2.3. ADME Testing Specific Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Galapagos
6.3.3.1. Company Snapshot
6.3.3.2. Financial Information
6.3.3.3. ADME Testing Specific Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Tecan Group
6.3.4.1. Company Snapshot
6.3.4.2. Financial Information
6.3.4.3. ADME Testing Specific Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. GVK Biosciences
6.4.1.1. Company Snapshot
6.4.1.2. ADME Testing Specific Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Pharmaron
6.4.2.1. Company Snapshot
6.4.2.2. ADME Testing Specific Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. Sai Life Sciences
6.4.3.1. Company Snapshot
6.4.3.2. ADME Testing Specific Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Shanghai Medicilon
6.4.4.1. Company Snapshot
6.4.4.2. ADME Testing Specific Service Portfolio
6.4.4.3. Recent Developments and Future Outlook
6.4.5. Syngene International
6.4.5.1. Company Snapshot
6.4.5.2. Financial Information
6.4.5.3. ADME Testing Specific Service Portfolio
6.4.5.4. Recent Developments and Future Outlook
6.4.6. WuXi AppTec
6.4.6.1. Company Snapshot
6.4.6.2. Financial Information
6.4.6.3. ADME Testing Specific Service Portfolio
6.4.6.4. Recent Developments and Future Outlook

7 BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
7.4. Concluding Remarks

8 MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. In Vitro ADME Testing Services: Mergers and Acquisitions
8.2.1. Cumulative Year-wise Trend
8.2.2. Geographical Activity
8.2.3. Ownership Change Matrix
8.2.4. Most Active Players: Analysis by Number of Acquisitions
8.2.5. Key Value Drivers
8.2.6. Key Acquisitions: Deal Multiples

9 REGULATORY RECOMMENDATIONS AND GUIDELINES
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Regulatory Agencies
9.2.1. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
9.2.2. World Health Organization (WHO)
9.2.3. Organisation for Economic Co-operation and Development (OECD)
9.3. Regulatory Guidelines Issued by Regional Regulatory Agencies
9.3.1. United States Food and Drug Administration (USFDA), US
9.3.2. European Medicine Agency (EMA), Europe
9.3.3. Ministry of Health, Labour and Welfare (MHLW), Japan
9.4. In Vitro ADME Testing Service Providers: Information on Regulatory Approval

10 MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall In Vitro ADME Testing Services Market, 2019-2030
10.4. In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030
10.4.1. In Vitro ADME Testing Services Market in North America, 2019-2030
10.4.1.1. In Vitro ADME Testing Services Market in the US, 2019-2030
10.4.1.2. In Vitro ADME Testing Services Market in Canada, 2019-2030
10.4.2. In Vitro ADME Testing Services Market in Europe, 2019-2030
10.4.2.1. In Vitro ADME Testing Services Market in Germany, 2019-2030
10.4.2.2. In Vitro ADME Testing Services Market in France, 2019-2030
10.4.2.3. In Vitro ADME Testing Services Market in the UK, 2019-2030
10.4.2.4. In Vitro ADME Testing Services Market in Italy, 2019-2030
10.4.2.5. In Vitro ADME Testing Services Market in Spain, 2019-2030
10.4.2.6. In Vitro ADME Testing Services Market in Rest of Europe, 2019-2030
10.4.3. In Vitro ADME Testing Services Market in Asia-Pacific and Rest of the World, 2019-2030
10.4.3.1. In Vitro ADME Testing Services Market in Japan, 2019-2030
10.4.3.2. In Vitro ADME Testing Services Market in China, 2018-2028
10.4.3.3. In Vitro ADME Testing Services Market in India, 2019-2030
10.4.3.4. In Vitro ADME Testing Services Market in Rest of the World, 2019-2030
10.5. In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030
10.5.1. In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030
10.5.2. In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030
10.5.3. In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030
10.5.4. In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030
10.6. In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030
10.6.1. In Vitro ADME Testing Services Market for Caco-2 Permeability Assay, 2019-2030
10.6.2. In Vitro ADME Testing Services Market for Protein Binding Assay, 2019-2030
10.6.3. In Vitro ADME Testing Services Market for Metabolic Stability / Clearance Assay, 2019-2030
10.6.4. In Vitro ADME Testing Services Market for Enzyme Induction Assay, 2019-2030
10.6.5. In Vitro ADME Testing Services Market for Enzyme Inhibition Assay, 2019-2030
10.6.6. In Vitro ADME Testing Services Market for Other Assays, 2019-2030
10.7. In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030
10.7.1. In Vitro ADME Testing Services Market for Small Molecules, 2019-2030
10.7.2. In Vitro ADME Testing Services Market for Biologics, 2019-2030
10.8. In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030
10.8.1. In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030
10.8.2. In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030
10.8.3. In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030
10.8.4. In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030
10.8.5. In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030
10.8.6. In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030
10.8.7. In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030
10.8.8. In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030
10.8.9. In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030
10.8.10. In Vitro ADME Testing Services Market for Cancers, 2019-2030
10.8.11. In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030
10.8.12. In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030
10.8.13. In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030
10.8.14. In Vitro ADME Testing Services Market for Other Disorders, 2019-2030
10.8.15. In Vitro ADME Testing Services Market: Market Attractiveness Analysis by Therapeutic Areas, 2019-2030
10.9. In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030
10.9.1. In Vitro ADME Testing Services Market for Industry Players, 2019-2030
10.9.2. In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030

11 CONCLUSION
11.1. In Vitro ADME Studies Conducted During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Success in Clinical Trials
11.2. Several CROs Offer Services for In Vitro ADME Testing; Most such Companies are based in North America and Europe
11.3. The Market is Dominated by Players having Vast In Vitro ADME Testing Portfolios; Drug Metabolism-related Assays Represent a Major Fraction of Services
11.4. Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in Number of Acquisitions Reported over the Past Decade
11.5. Owing to the Benefits of Outsourcing, the In Vitro ADME testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

12 EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. 490 BioTech
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Dan Close, Chief Scientific Officer
12.3. JRF Global
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

13 APPENDIX 1: TABULATED DATA

14 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Pharmacokinetics Pathway of a Drug in Human Body
Figure 3.3 Comparison of Oral and Intravascular Drug Administration: Role of Hepatic Portal System
Figure 3.4 Reasons for Attrition in Drug Development
Figure 3.5 ADME Studies in Discovery and Preclinical Development
Figure 3.6 Drivers for In Vitro ADME Testing Studies
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance-based Outsourcing Model
Figure 4.4 Key Steps Leading to Outcomes-based Outsourcing Model
Figure 4.5 Factors Influencing Outsourcing Decisions
Figure 4.6 Key Considerations to Select a CRO Partner
Figure 4.7 Role of a CRO in Different Phases of Drug Development
Figure 4.8 End-to-End Integrated Services in Discovery and Preclinical Research
Figure 4.9 Benefits of Outsourcing ADME Testing Services
Figure 4.1 Challenges Related to Outsourcing ADME Testing Services
Figure 5.1 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Figure 5.2 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Figure 5.3 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Figure 5.4 In Vitro ADME Testing Service Providers: Distribution by Company Size
Figure 5.5 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Figure 5.6 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Figure 5.7 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Figure 5.8 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Figure 5.9 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Figure 5.1 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Figure 5.11 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Figure 5.12 In Vitro ADME Testing Service Providers Logo Landscape: Distribution by Company Size and Location
Figure 6.1 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.2 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.3 AMRI: In Vitro ADME Testing Service Portfolio
Figure 6.4 Charles River Laboratories: Business Segments
Figure 6.5 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Figure 6.6 Charles River Laboratories: In Vitro ADME Testing Service Portfolio
Figure 6.7 BioDuro: In Vitro ADME Assays Offered
Figure 6.8 RTI International: Annual Revenues, 2013-2017 (USD Million)
Figure 6.9 RTI International: In Vitro ADME Testing Service Portfolio
Figure 6.1 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Figure 6.11 Eurofins Scientific: In Vitro ADME Testing Service Portfolio
Figure 6.12 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Figure 6.13 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Figure 6.14 Evotec: Drug Discovery Services
Figure 6.15 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Figure 6.16 Galapagos: In Vitro ADME Testing Service Portfolio
Figure 6.17 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Figure 6.18 Tecan Group: In Vitro ADME Testing Service Portfolio
Figure 6.19 GVK Biosciences: Business Segments
Figure 6.2 GVK Biosciences: In Vitro ADME Testing Service Portfolio
Figure 6.21 Pharmaron: In Vitro ADME Service Portfolio
Figure 6.22 Sai Life Sciences: In Vitro ADME Testing Service Portfolio
Figure 6.23 Shanghai Medicilon: In Vitro ADME Testing Service Portfolio
Figure 6.24 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Figure 6.25 Syngene International: In Vitro ADME Testing Service Portfolio
Figure 6.26 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Figure 6.27 WuXi AppTec: In Vitro ADME Testing Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 7.1 Benchmark Analysis: Comparison Across Peer Groups
Figure 8.1 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Figure 8.2 Acquisitions: Regional Distribution
Figure 8.3 Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 8.4 Acquisitions: Ownership Change Matrix
Figure 8.5 Acquisitions: Most Active Acquirers
Figure 8.6 Acquisitions: Key Value Drivers
Figure 8.7 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Figure 9.1 Regulatory Guidelines for Non-Clinical Studies
Figure 9.2 ICH: Regulatory and Industry Participants
Figure 9.3 ICH: Guidance Documents for Non-Clinical Studies
Figure 9.4 USFDA: GLP Guidelines for Non-Clinical Studies
Figure 9.5 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Figure 10.1 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Figure 10.2 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.3 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Figure 10.4 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Billion)
Figure 10.5 In Vitro ADME Testing Services Market, 2019-2030: US, Base Scenario (USD Million)
Figure 10.6 In Vitro ADME Testing Services Market, 2019-2030: Canada, Base Scenario (USD Million)
Figure 10.7 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Billion)
Figure 10.8 In Vitro ADME Testing Services Market, 2019-2030: Germany, Base Scenario (USD Million)
Figure 10.9 In Vitro ADME Testing Services Market, 2019-2030: France, Base Scenario (USD Million)
Figure 10.1 In Vitro ADME Testing Services Market, 2019-2030: UK, Base Scenario (USD Million)
Figure 10.11 In Vitro ADME Testing Services Market, 2019-2030: Italy, Base Scenario (USD Million)
Figure 10.12 In Vitro ADME Testing Services Market, 2019-2030: Spain, Base Scenario (USD Million)
Figure 10.13 In Vitro ADME Testing Services Market, 2019-2030: Rest of Europe, Base Scenario (USD Million)
Figure 10.14 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Billion)
Figure 10.15 In Vitro ADME Testing Services Market, 2019-2030: Japan, Base Scenario (USD Million)
Figure 10.16 In Vitro ADME Testing Services Market, 2019-2030: China, Base Scenario (USD Million)
Figure 10.17 In Vitro ADME Testing Services Market, 2019-2030: India, Base Scenario (USD Million)
Figure 10.18 In Vitro ADME Testing Services Market, 2019-2030: Rest of the World, Base Scenario (USD Million)
Figure 10.19 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Figure 10.2 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Figure 10.21 In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.22 In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.23 In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.24 In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.25 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Figure 10.26 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Figure 10.27 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Caco-2 Permeability Assay, Base Scenario (USD Million)
Figure 10.28 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Protein Binding Assay, Base Scenario (USD Million)
Figure 10.29 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Metabolic Stability / Clearance Assay, Base Scenario (USD Million)
Figure 10.3 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Induction Assay, Base Scenario (USD Million)
Figure 10.31 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Inhibition Assay, Base Scenario (USD Million)
Figure 10.32 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Other Assays, Base Scenario (USD Million)
Figure 10.33 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Figure 10.34 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Figure 10.35 In Vitro ADME Testing Services Market for Small Molecules, 2019-2030: Base Scenario (USD Billion)
Figure 10.36 In Vitro ADME Testing Services Market for Biologics, 2019-2030: Base Scenario (USD Billion)
Figure 10.37 In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.38 In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.39 In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.4 In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.41 In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030: Base Scenario (USD Million)
Figure 10.42 In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.43 In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.44 In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.45 In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.46 In Vitro ADME Testing Services Market for Cancers, 2019-2030: Base Scenario (USD Million)
Figure 10.47 In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.48 In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.49 In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.5 In Vitro ADME Testing Services Market for Other Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.51 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
Figure 10.52 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Figure 10.53 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030
Figure 10.54 In Vitro ADME Testing Services Market for Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 10.55 In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 11.1 Overall In Vitro ADME Testing Services Market, Conservative, Base and Optimistic Scenarios, 2019, 2024 and 2030 (USD Billion)

List of Tables

Table 3.1 List of Assays Performed During ADME Studies
Table 5.1 In Vitro ADME Testing Services: List of Industry Players
Table 5.2 In Vitro ADME Testing Service Providers: Information on Type of In Vitro ADME Testing Services
Table 5.3 In Vitro ADME Testing Service Providers: Information on Type of Molecule
Table 5.4 In Vitro ADME Testing Service Providers: Information on Type of Clientele
Table 5.5 In Silico ADME Testing Services: List of Industry Players
Table 6.1 In Vitro ADME Testing Services: List of Companies Profiled
Table 6.2 AMRI: Key Highlights
Table 6.3 AMRI: Recent / Past Trends and Future Outlook
Table 6.4 Charles River Laboratories: Key Highlights
Table 6.5 Charles River Laboratories: Recent / Past Trends and Future Outlook
Table 6.6 BioDuro: Key Highlights
Table 6.7 BioDuro: Recent / Past Trends and Future Outlook
Table 6.8 RTI International: Key Highlights
Table 6.9 RTI International: Recent / Past Trends and Future Outlook
Table 6.10 Eurofins Scientific: Key Highlights
Table 6.11 Eurofins Scientific: Recent / Past Trends and Future Outlook
Table 6.12 Evotec: Key Highlights
Table 6.13 Evotec: In Vitro ADME Assays Offered
Table 6.14 Evotec: Recent / Past Trends and Future Outlook
Table 6.15 Galapagos: Key Highlights
Table 6.16 Galapagos: Recent / Past Trends and Future Outlook
Table 6.17 Tecan Group: Key Highlights
Table 6.18 Tecan Group: Recent / Past Trends and Future Outlook
Table 6.19 GVK Biosciences: Key Highlights
Table 6.20 GVK Biosciences: Recent / Past Trends and Future Outlook
Table 6.21 Pharmaron: Key Highlights
Table 6.22 Pharmaron: Recent / Past Trends and Future Outlook
Table 6.23 Sai Life Sciences: Key Highlights
Table 6.24 Sai Life Sciences: Recent / Past Trends and Future Outlook
Table 6.25 Shanghai Medicilon: Key Highlights
Table 6.26 Shanghai Medicilon: Recent / Past Trends and Future Outlook
Table 6.27 Syngene International: Key Highlights
Table 6.28 Syngene International: Recent / Past Trends and Future Outlook
Table 6.29 WuXi AppTec: Key Highlights
Table 6.30 WuXi AppTec: Recent / Past Trends and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 In Vitro ADME Testing Services: Mergers and Acquisitions
Table 8.2 In Vitro ADME Testing Services: Information on Key Value Drivers of Acquisitions
Table 8.3 Key Acquisitions: Deal Multiples
Table 9.1 USFDA: Guidance Documents for Non-Clinical Studies
Table 9.2 EMA: Guidance Documents for Non-Clinical Studies
Table 9.3 MHLW: Guidance Documents for Non-Clinical Studies
Table 9.4 In Vitro ADME Testing Service Providers: Information on Regulatory Approval
Table 12.1 490 BioTech: Key Highlights
Table 12.2 JRF Global: Key Highlights
Table 13.1 Reasons for Attrition in Drug Development
Table 13.2 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Table 13.3 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Table 13.4 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Table 13.5 In Vitro ADME Testing Service Providers: Distribution by Company Size
Table 13.6 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Table 13.7 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Table 13.8 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Table 13.9 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Table 13.10 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Table 13.11 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Table 13.12 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Table 13.13 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 13.14 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 13.15 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Table 13.16 RTI International: Annual Revenues, 2013-2017 (USD Million)
Table 13.17 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Table 13.18 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Table 13.19 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Table 13.20 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Table 13.21 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Table 13.22 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Table 13.23 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Table 13.24 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Table 13.25 Benchmark Analysis: Peer Group I
Table 13.26 Benchmark Analysis: Peer Group II
Table 13.27 Benchmark Analysis: Peer Group III
Table 13.28 Benchmark Analysis: Peer Group IV
Table 13.29 Benchmark Analysis: Peer Group V
Table 13.30 Benchmark Analysis: Peer Group VI
Table 13.31 Benchmark Analysis: Peer Group VII
Table 13.32 Benchmark Analysis: Peer Group VIII
Table 13.33 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Table 13.34 Acquisitions: Regional Distribution
Table 13.35 Acquisitions: Intercontinental and Intracontinental Acquisitions
Table 13.36 Acquisitions: Ownership Change Matrix
Table 13.37 Acquisitions: Most Active Acquirers
Table 13.38 Acquisitions: Key Value Drivers
Table 13.39 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Table 13.40 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Table 13.41 Overall In Vitro ADME Testing Services Market, 2019-2030: Conservative Scenario (USD Billion)
Table 13.42 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Table 13.43 Overall In Vitro ADME Testing Services Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 13.44 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Conservative Scenario (USD Billion)
Table 13.45 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Table 13.46 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 13.47 In Vitro ADME Testing Services Market, 2019-2030: North America, Conservative Scenario (USD Million)
Table 13.48 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Million)
Table 13.49 In Vitro ADME Testing Services Market, 2019-2030: North America, Optimistic Scenario (USD Million)
Table 13.50 In Vitro ADME Testing Services Market, 2019-2030: Europe, Conservative Scenario (USD Million)
Table 13.51 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Million)
Table 13.52 In Vitro ADME Testing Services Market, 2019-2030: Europe, Optimistic Scenario (USD Million)
Table 13.53 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
Table 13.54 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
Table 13.55 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
Table 13.56 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Table 13.57 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Conservative Scenario (USD Million)
Table 13.58 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Table 13.59 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Optimistic Scenario (USD Million)
Table 13.60 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Table 13.61 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Conservative Scenario (USD Million)
Table 13.62 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Table 13.63 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Optimistic Scenario (USD Million)
Table 13.64 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Table 13.65 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Conservative Scenario (USD Billion)
Table 13.66 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Table 13.67 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Optimistic Scenario (USD Billion)
Table 13.68 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Table 13.69 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
Table 13.70 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
Table 13.71 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
Table 13.72 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
Table 13.73 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Billion)
Table 13.74 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Table 13.75 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Billion)
Table 13.76 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 490 BioTech
  2. Aaranya Biosciences
  3. AbbVie
  4. Accelera
  5. Advanced Chemistry Development Labs
  6. Admescope
  7. ADMETRx
  8. Advancell Advanced In Vitro Cell Technologies
  9. Agilux Laboratories
  10. Allesh Biosciences Labs
  11. Altasciences
  12. AMRI
  13. Analiza
  14. Antengene
  15. APEIRON Biologics
  16. APhaD
  17. Apredica
  18. Aptuit
  19. Aragen Bioscience
  20. Aravali Pharma & Lifesciences
  21. Asahi Kasei Pharma
  22. Astellas Analytical Science Laboratories
  23. AstraZeneca
  24. Aurigon
  25. Aurora Fine Chemicals
  26. Avistron Chemistry Services
  27. Baxter
  28. Biaffin
  29. Bienta
  30. BioAscent
  31. Biocon
  32. BioDuro
  33. BioIVT
  34. Bionomics
  35. Biotech Investment Group
  36. Biotranex
  37. BLIRT
  38. BloodCenter of Wisconsin
  39. Blue Stream Laboratories
  40. BOC Sciences
  41. Brains On-Line
  42. BRI Biopharmaceutical Research
  43. Brunswick Labs
  44. Caliper Life Sciences
  45. Calvert Laboratories
  46. CanAm Bioresearch
  47. Cangenix
  48. CapEval Pharma
  49. Carna Biosciences
  50. Carrick Therapeutics
  51. CeeTox
  52. Celgene
  53. Cellumen
  54. Celsis In Vitro Technologies
  55. Celsis International
  56. CEMSA - Center for Applied Mass Spectrometry
  57. Charles River Laboratories
  58. ChemBio Discovery Solutions
  59. ChemDiv
  60. ChemModeling
  61. ChemoGenics BioPharma
  62. Chemotargets
  63. ChemPartner
  64. Citoxlab Group
  65. Clinical Research Laboratories
  66. Cloud Pharmaceuticals
  67. Colorado Computational
  68. Comparative Biosciences
  69. CompChem Solutions
  70. Concept Life Sciences
  71. Concord Biosciences
  72. Corning Life Sciences
  73. Covance
  74. CR Medicon
  75. Creative Animodel
  76. Creative Biolabs
  77. Creative Biostructure
  78. Crelux
  79. Crucell
  80. Cyclica
  81. Cyprotex
  82. Dermscan
  83. DiaSorin
  84. Discover Drugs
  85. Distributed Bio
  86. Domainex
  87. Drik
  88. eADMET
  89. Eagle Pharmaceuticals
  90. ECOSUR
  91. EMD Millipore
  92. Enamine 
  93. Entelos
  94. Envigo
  95. EnvironeX Group
  96. Eurofins Scientific
  97. Eurofins Cerep
  98. European Federation of Pharmaceutical Industries and Associations
  99. Eurosafe
  100. Evolvus
  101. Evotec
  102. Excelra Knowledge Solutions
  103. Exscientia
  104. Fidelta
  105. Formex
  106. Frontage Laboratories 
  107. Gadea Pharmaceutical Group
  108. Galapagos
  109. Genentech
  110. GenPharm Tox Biotech
  111. Gfree Bio
  112. Gilead Sciences
  113. Greenpharma
  114. GSK
  115. GTCR
  116. GVK Biosciences
  117. HarkerBIO
  118. HD Biosciences
  119. Health Economics Research Centre
  120. Icagen
  121. IDSC
  122. ImaBiotech
  123. In Vitro ADMET Laboratories
  124. Innovative Informatica Technologies
  125. Inpharmatica
  126. InrexTest
  127. INSERM
  128. International Resources Group
  129. INVITEK
  130. IONTOX
  131. IOTA Pharmaceuticals
  132. Japan Pharmaceutical Manufacturers Association
  133. Janssen Therapeutics
  134. JOINN Laboratories
  135. JPT Peptide Technologies
  136. JRF GLOBAL
  137. Jubilant Biosys
  138. Kirklees Biosciences
  139. KWS BioTest
  140. LabCorp
  141. Labo Van Poucke
  142. Laxai Avanti Life Sciences
  143. LegoChem Biosciences
  144. Longthera Pharmaceuticals
  145. Mascot Industries
  146. MasiMax Resources
  147. Mayo Clinic
  148. Medisyn Technologies
  149. Merck
  150. MetaSafe
  151. Metrion Biosciences
  152. MicroConstants
  153. Mind the Byte
  154. Molcode
  155. Molsoft
  156. MorphoSys
  157. MPI Research
  158. MTTlab
  159. Nanolab Technologies
  160. National Institute of Allergy and Infectious Disease
  161. National Institutes of Health
  162. Neuro-Sys
  163. NMDL-LCPL
  164. Notox
  165. NovaData Solutions
  166. Novamass
  167. NovaMechanics
  168. Novartis
  169. Novo Informatics
  170. NuChem Therapeutics
  171. Nuevolution
  172. NuGEN Technologies
  173. Numerate
  174. Oncodesign
  175. Optivia Biotechnology
  176. Oroxcell
  177. Oxford Bioscience Partners
  178. Panlabs Biologics
  179. PathoQuest
  180. PerkinElmer
  181. Petra Pharma
  182. Pfizer
  183. PharmaCadence
  184. Pharmacelsus
  185. Pharmaceuticals and Medical Devices Agency
  186. Pharmaceutical Product Development
  187. Pharmaron
  188. Pharmidex Pharmaceutical Services
  189. PharmOptima
  190. PHAST
  191. Piramal Pharma Solutions
  192. Porton Pharma Solutions
  193. Preclinical GPS
  194. Prestwick Chemical
  195. Prime European Therapeuticals
  196. Princeton BioMolecular Research
  197. Profacgen
  198. ProSciens
  199. Prosilico
  200. ProtoQSAR
  201. ProXyChem
  202. Q2 Solutions
  203. Q3 Analytical
  204. Qualyst Transporter Solutions
  205. Quantum Hi-Tech
  206. Quintara Discovery
  207. Quotient Bioresearch
  208. ReadyCell
  209. Rebexsess Discovery Chemistry
  210. Red Glead Discovery
  211. Regulus Therapeutics
  212. ResearchPoint Global
  213. Rosa
  214. RTI International
  215. Sai Life Sciences
  216. Sandexis
  217. Sanofi
  218. Schrödinger
  219. Sekisui Medical
  220. Sekisui XenoTech
  221. Selcia
  222. Selvita
  223. Shanghai ChemPartner
  224. Shanghai Medicilon
  225. Shechter Computational Solutions
  226. Shire
  227. Sigma-Aldrich
  228. SilcsBio
  229. Simulations Plus
  230. SNBL USA
  231. SOLVO Biotechnology
  232. Spectris
  233. SPEware
  234. SRI International
  235. Strand Life Sciences
  236. Suven Life Sciences
  237. Sygnature Discovery
  238. Syngene
  239. Synovo
  240. Syntegrity Group
  241. TCG Lifesciences
  242. Tecan
  243. TestAmerica
  244. TetraQ
  245. The Carlyle Group
  246. The Institute for Transfusion Medicine
  247. The Michael J Fox Foundation
  248. Touchstone Biosciences
  249. TPG Capital
  250. Triskelion
  251. Unilabs
  252. University of California
  253. University of Pittsburgh
  254. Vanta Bioscience
  255. Villapharma Research
  256. Vipragen Biosciences
  257. Vitalant Research Institute
  258. Viva Biotech
  259. Vivo Bio Tech
  260. Vivotecnia
  261. WIL Research Laboratories
  262. Wildcard Pharmaceutical Consulting
  263. WuXi AppTec
  264. Xceleron
  265. XenoBiotic Laboratories
  266. Xenometrics
  267. XenoTech
  268. XtalPi
  269. Zumutor Biologic

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,999

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com